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ABSTRACT 
Objective: The present research work aims at describing the formulation and evaluation of the ocular delivery system of moxifloxacin 
hydrochloride (MH) based on the concept of ion sensitive in situ gelations. 
Methods: In situ gel was prepared by a hot method using 0.6% of gelrite, 0.25% hydroxypropylmethylcellulose (HPMC K4M) and 0.023% tamarind 
gum as bioadhesive polymers for sustained drug release. Optimization was done by Box Behnken Design with different concentration of gelrite (X1), 
HPMC K4M (X2) and tamarind gum (X3) as independent variables. In situ gel was optimized based on mucoadhesion index (Y1), Gel strength (Y2) 
and in vitro drug release (Y3). Influence of the quantitative variable on the dependent variable was predicted by a polynomial equation.  
Results: Infrared spectroscopy excluded any interaction between drug and excipients. The selected independent variables significantly influenced 
the responses and were able to sustain the drug release. The prepared gel with a pH of 6.8 to 7.4 exhibited non-newtonian flow with no ocular 
irritation. The formulation remained stable with no change in pH and viscosity after 30 d of stability study.  
Conclusion: Thus, moxifloxacin hydrochloride (MH) in situ gel is a viable alternative to a conventional delivery system with the properties of 
sustained drug release, prolonged ocular retention, and improved corneal penetration.  
Keywords: Moxifloxacin hydrochloride (MH), Box-Behnken Design, Gelrite, HPMC K4M, Tamarind gum 




Development of suitable drug delivery systems for ocular therapy is 
one of the major problems being faced by pharmaceutical scientists. 
Eye, being the most interesting organ due owing to its drug 
disposition characteristics is considered a convenient route for the 
topical application of drugs [1]. But the attainment of an optimal 
concentration at the site of action circumventing the protective 
barriers of the eye without causing permanent tissue damage offers 
a significant challenge to the formulator.  
Conventional ocular dosage forms result in poor bioavailability due 
to tear production, nonproductive absorption, transient residence 
time, and impermeability of corneal epithelium. These physiological 
and anatomical constraints deliver only a small fraction of the 
instilled dose of ocular therapeutics and less than 1% is effectively 
absorbed and reaches the internal anterior tissue of the eyes [2].  
Several methods for prolonging the contact time between drug and 
corneal–conjunctival epithelium are investigated to increase the 
drug bioavailability. Various ophthalmic products, such as inserts, 
ointments, suspensions, and aqueous gels, have been developed to 
enhance ophthalmic bioavailability. These ocular drug delivery 
systems, however, have not been used extensively because of some 
drawbacks, such as blurred vision and poor patient compliance.  
As the ocular efficacy of topically applied drugs is influenced by the 
corneal contact time, in situ gel is the most common method of 
improving the ocular availability of drugs. In situ gel system is 
formulated as liquid preparation suitable to be instilled into eyes 
which upon exposure to the physiologic environment changes to gel, 
thus prolongs the precorneal residence time and enhances the 
ocular bioavailability of the drug. 
Topical administration of antibacterial medication to the conjunctival sac 
is usually an effective avenue for treating bacterial conjunctivitis, 
keratitis, and uveitis but requires frequent instillation. Moxifloxacin, an 
8-methoxy fluoroquinolone (4th generation), having broad-spectrum 
antibiotic activity, with efficacy against various gram-positive and gram-
negative microorganisms through inhibition of DNA gyrase and 
topoisomerases IV and is indicated for severe infections. To increase the 
bioavailability of moxifloxacin hydrochloride in situ gelling systems can 
be highly advantageous [3].  
In situ gels consist of polymeric networks that can absorb large 
quantities of water while remaining insoluble in aqueous solutions 
due to chemical or physical cross-linking of individual polymer 
chains [4-5]. Increase in solution viscosity by using polymers 
improves retention of product on the corneal surface. More recently, 
the newer approach to improve mechanical strength and enhance 
precorneal resident time of in situ gel is based on the use of 
mucoadhesive polymers. The principle for the use of bioadhesive 
polymers relies on their ability to interact with the mucin present on 
the eye surface. The present investigation uses the ion-sensitive 
gelling mechanism with HPMC K4M and tamarind gum as potential 
bioadhesive polymers for the formulation of hydrogels. The 
formulation also consists of gellan gum as an ion-sensitive polymer 
which is having good gel strength and biocompatibility [6-8]. 
In this regard, the present investigation is intended to characterize and 
evaluate the in situ gel of moxifloxacin hydrochloride, using bioadhesive 
polymers for sustaining drug release for a longer period. Optimization of 
the formulation was done using Box-Behnken statistical design (Design 
Expert® 8.0.7.1). The formulation variables that could affect the release 
rate and absorption of the drug in topical formulations, such as 
mucoadhesion strength, gelation strength, and the drug concentration in 
the formulations, were studied. In addition, the in vivo performance of 
gel formulation was assessed on the basis of the ocular irritancy in the 
rabbit’s eye [9]. 
MATERIALS AND METHODS 
Materials 
Moxifloxacin hydrochloride (MH) was gifted by MARCK Bioscience 
Ltd, Kheda. Hydroxy-propylmethylcellulose (HPMC K4M) was 
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supplied from colorconasia Pvt. Ltd. Gellan gum (Gelrite) and mucin 
were supplied from Hi-media Laboratories Pvt. Ltd. Tamarind gum 
was received from Shivam Exim Ltd, Ahmedabad. 
Compatibility study 
The physicochemical compatibility between moxifloxacin hydrochloride 
(MH) and polymers was studied using Fourier transforms infrared 
spectroscopy (FTIR) and Differential scanning calorimetric analysis 
(DSC).  
Fourier transform infrared spectroscopy (FTIR)  
The infra-red spectra of pure moxifloxacin hydrochloride (MH) and 
drug-polymer physical mixture, were recorded using FTIR 
spectrophotometer (Perkin Elmer–spectrum Bx, USA). Disks of 
potassium bromide and tested sample mixtures were obtained using 
hydraulic press before scanning at a range of 4000 through 400 cm-1.  
Differential scanning calorimetric (DSC) 
Unprocessed moxifloxacin hydrochloride (MH) and prepared drug-
polymer physical mixture were studied regarding their thermal 
behavior using differential scanning calorimetry (Perkin Elmer DSC-
7, USA). Aluminum pans loaded with samples equivalent to 
approximately 2 mg of the drug were crimped. The thermal behavior 
of each sample was investigated at a heating rate of 10 °C/min, 
covering temperature ranges of 25–200 °C. Data analysis was 
conducted using the TA-60WS thermal analysis software and the 
transition midpoint (Tm) of the drug was recorded.  
Development of ophthalmic in situ gel  
In situ ophthalmic gel was prepared by the hot method as per the 
composition of each formulation mentioned in table 1. Gelrite and 
benzalkonium chloride (0.0075%w/v) were dissolved in 50 ml of 
sterile water under an agitated condition at 1000rpm at 90 °C. After 
complete dissolution, tamarind gum and hydroxypropyl 
methylcellulose (HPMC K4M) were dissolved in the same condition. 
The solution was kept at room temperature. Moxifloxacin 
hydrochloride (MH) (0.5% w/v) and mannitol (0.5 gm) were 
dissolved separately in water for injection separately at room 
temperature. The above formulation was then filtered through a 
polycarbonate filter of 0.45 µm, and autoclaved at 121 °C for 20 min 
[10-11]. 
Experimental design 
The Box-Behnken design was used to optimize the formulation 
parameters and to assess the main effect and interaction effect. The 
independent and dependent variables are listed in table 1. Table 2, 
summarizes an account of the 15 experimental runs studied, their 
factor combinations, and the translation of the coded levels to the 
experimental units employed during the study. Mucoadhesion 
strength, gel strength, and % drug release were chosen as the 
response variables. Design expert software (8.0.7.1), trial version, 
was used for computation. Polynomial models, including interaction 
and quadratic terms, were generated for all the response variables 
using multiple linear regression analysis (MLRA) approach. The 
general form of the model is represented in equation 1. The goal of 
the experimental design was to find out, with the minimum number 
of experimental runs, which process variables have the biggest 
impact on the quality of the final product. 
Yi = b0+b1X1+b2X2+b3X3+b12X1X2+b23X2X3+b13X1X3+b11X12+b22X22+b33X32. 
(1) 
Where, b0 is the intercept representing the arithmetic mean 
response of 15 runs, b1 to b33 are the regression coefficients, X1, X2 
and X3 are the independent variable. The terms X1, X2 and Xi2 (i=1 to 
3) represent the interaction and quadratic term respectively. Box 
Behnken design was selected due to less number of run for 3 factors 
and 3 levels.  
The constraint for selection of optimum formula were primarily based 
on the desired values of the response parameters, i.e. gel strength 
(<150 dyne/cm2), mucoadhesion index (up to 15,000) and cumulative 
percentage drug release up to 12 h (>95%). The formulations 
corresponding to optimum responses were prepared and evaluated. 
The resultant experimental data was quantitatively compared with 
predicted values, and percentage error calculated [12]. 
 
Table 1: Variables and constrains in box-behnken experimental design 
 Independent variables  Levels Constrains 
Low Medium High 
X1 = Concentration of Gelrite (% W/V) 0.2 0.4 0.6 
X2 = Concentration of Tamarind gum (% W/V) 0.0 0.05 1.0 
X3 = Concentration of HPMC K4M (%W/V) 0.0 0.25 0.5 
Transformed values -1 0 1 
Dependent variables Y1 =Mucoadhesive index (Cps) 15,000 
Y2=Gelation strength (dyne/cm2) <150 dyne/cm2 
Y3= Drug release up to 12 hr (%) >95% 
 
Data analysis and validation of the model 
The statistical validity of the polynomial equation was established 
on the basis of ANOVA analysis. Subsequent feasibility and grid 
search were performed to locate design space for optimum 
formulations. 3-D and 2-D response surface graphs and contour 
plots were constructed. Checkpoint batches as per the formula were 
prepared and evaluated for various responses. Experimental data of 
all responses were quantitatively compared with that of the 
predicted values and validity of the model was established. 
Evaluation of in situ ophthalmic gel 
Clarity, pH, and viscosity 
Clarity test was performed by visual inspection of each container 
under a good light, viewed against reflection into the eyes and 
viewed against a black and white background. The pH of prepared 
formulations was measured by a digital pH meter (Labindia–Pico+, 
Japan). To assess the rheological property of in situ gel, the viscosity 
of all the prepared batches were measured at 4 shear rate i.e. 50 
rpm, 100 rpm, 150 rpm, and 200 rpm using a Brookfield LVDV II 
PRO+viscometer. All the measurements were performed in triplicate 
and mean viscosity was calculated. The rheological flow behavior 
was determined from the graph of viscosity and shear rate [13].  
Drug content 
The drug content was determined for the prepared in situ gel by 
dissolving an amount equivalent to 50 mg of the drug from each 
formulation in 50 ml water. After suitable dilution, drug 
concentration was determined spectrophotometrically at 298 nm. 
The experiment was performed in triplicate. 
Mucoadhesion strength 
In this method mucin dispersion (MUC) 20% (w/w) was prepared 
by hydrating dried mucin with phosphate buffer (pH 7.4) for 12h at 
room temperature. Fifteen grams of this dispersion was mixed for 
20 min with 5g of prepared sol before measurement that yields 15% 
(w/w) of mucin. The viscosity of the prepared sol/mucin system (ηt) 
and mucin (ηm) were measured at 32 °C at shear rates of 25, 50, 100 
and 150 S-1. The viscosity of the prepared sol/phosphate buffer (pH 
7.4) (ηp) was determined in the same way [14]. The viscosity 
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component due to bioadhesion ηb was obtained by the following 
equation:  
ηb= ηt–ηm-ηp………. (2) 
The mucoadhesion index M [Pa] was calculated using the shear rate 
D[S-1] and the viscosity component ηb [mPas] according to the 
following equation:  
M=ηb*D………. (3) 
Gel strength 
To mimic the in vivo conditions, in situ gel were diluted with simulated 
tear fluid (40:7) and transferred to a 100 ml cylinder. The gelation was 
performed at 37 °C. A disc (1 g in weight and 1.5 cm in diameter) was 
placed on the surface of the gelled solution in the cylinder, and various 
weights were placed on gel and gel strength was determined as the 
minimal weight needed for the gel to travel the disc 5 cm down. All 
measurements were performed in triplicate [15]. 
In vitro diffusion study 
To ensure sustain release behavior of in situ gel, Franz diffusion cell 
was used. A cellulose acetate membrane (Dialysis membrane with 
25 mm diameter) was adapted to the terminal portion of the 
cylindrical donor compartment. 3 ml of a formulation containing 
drug sufficient for establishing sink conditions, was placed into the 
donor compartment. The receptor compartment contained 15 ml of 
phosphate buffer solution of pH 7.4, maintained at 37 °C under mild 
agitation using a magnetic stirrer. At specific time intervals, aliquots 
of 1 ml were withdrawn and immediately restored with the same 
volume of fresh phosphate buffer. The amount of drug released was 
assessed by measuring the absorbance at 289 nm using a UV 
spectrophotometer [16]. 
Ocular irritation study 
To assess in vivo irritancy study, New Zealand Albino rabbits 
weighing 3.0-3.5 kg were used. They were treated as prescribed in 
the “Guide for the Care and Use of Laboratory Animals” (NIH 
Publication No. 92-93, revised 1985). The preclinical experimental 
protocol (Protocol no. 1124 dated 8th Oct. 2011) was approved by 
institutional animal ethics committee as per the guidance of CPCSEA, 
Ministry of social justice and empowerment, Government of India 
(Ethical committee Registration number is 277/CPCSEA). Prior to 
the experiments, the animals were housed in standard cages in a 
light-controlled room at 19±1 ᵒC and 50±5% relative humidity, with 
no restriction of food or water. During the experiments, the rabbits 
were placed in restraining boxes, where they could move their heads 
and eyes freely. All experiments were carried out under veterinary 
supervision. The study was performed according to Modified Draize 
technique on six male albino rabbits. Rabbits were divided into two 
groups. Group I served as control group, and Group II was treated 
with drug formulation. The optimized formulation was instilled daily 
for a period of 21 d, and the rabbits were observed for redness, 
swelling, and watering of the eye [17-19]. 
Stability study 
To assess the formulation stability studies were conducted as per 
ICH guideline. Optimized formulation was filled in 50 ml of LDPE 
plastic bottle and kept in the stability chamber at 25 ֯C±5֯C for 3 mo. 
The physical and chemical stability was tested by monitoring change 
in pH, gelation time, mucoadhesive strength, viscosity, and drug 
content. 
RESULTS AND DISCUSSION 
Drug-polymer compatibility studies  
Fourier transform infrared spectroscopy (FTIR)  
The infrared study was performed to examine any possible 
interaction between pure drug and additives. Fig. 1 shows the FTIR 
spectra of moxifloxacin hydrochloride and physical mixture.  
Pure moxifloxacin hydrochloride (MH) spectra showed 
characteristic peaks represented as C =O stretching vibrations 
shown at 1709 cm-1, N-H stretching vibrations at 2949 cm-1, O-H 
stretching vibration at 3530 cm-1. The FTIR spectrums of physical 
mixture revealed the main absorption bands of moxifloxacin 
hydrochloride with no significant changes compared with the 
spectrum of pure drug. This would suggest the absence of any 




Fig. 1: FTIR spectrum of (A) Moxifloxacin hydrochloride (B) Moxifloxacin hydrochloride-polymer physical mixture 
 
Differential scanning calorimetry (DSC) 
DSC of pure moxifloxacin hydrochloride (MH) and physical mixture 
are shown in fig. 2. Unprocessed drug exhibited a characteristic 
sharp endothermic peak at 262.92 °C corresponding to its melting 
point. The thermo gram of the investigated physical mixture 
exhibited the characteristic endothermic peak of MH, indicating the 
absence of interaction between the two components present in the 
physical mixture. 
Experimental design 
For the response surface methodology involving BBD, a total of 
15 experiments were performed for three factors at three levels 
each. The experiment runs with independent variables and the 
observed responses for the 15 formulations are shown in table 2. 
A suitable polynomial equation involving the individual main 
effects and interaction factors was selected based on the 
estimation of several statistical parameters, such as the multiple 
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correlation coefficient (r2), adjusted multiple correlation 
coefficient (adjusted r2) and the predicted residual sum of 
squares (PRESS), provided by the Design-Expert software® 
(8.0.7.1) Trial Version. 
  
 
Fig. 2: DSC spectra of (A) Moxifloxacin hydrochloride (B) Moxifloxacin hydrochloride-polymer physical mixture 
 
Table 2: Observed responses in box behnken design for in situ gel 
Batch no. Coded factor Response 
 X1 (Conc. of Gelrite) 
(%) 
X2 (Conc. of Tamarind Gum) 
(%) 
X3  








1 0 -1 -1 630 9.86±0.02 96.62±1.21 
2 -1 0 1 6675 117.73±2.21 87.54±0.21 
3 -1 0 -1 3330 25.00±1.54 98.65±1.63 
4 0 -1 1 1065 65.94±2.32 99.57±1.90 
5 -1 1 0 4545 109.18±1.23 99.28±2.12 
6 0 0 0 5295 145.68±1.21 95.45±1.36 
7 0 0 0 5280 146.01±2.21 100.86±2.24 
8 0 1 -1 3870 69.2±1.65 100.13±1.36 
9 1 -1 0 4230 117.4±2.54 98.23±2.32 
10 1 1 0 9780 98.66±2.36 84.39±2.64 
11 0 0 0 5865 146.34±2.24 96.01±3.32 
12 1 0 1 1023 156.13±3.21 87.66±1.23 
13 -1 -1 0 1935 25.23±1.21 97.98±2.82 
14 1 0 -1 1860 19.8±2.74 99.91±2.36 
15 0 1 1 7095 97.66±1.24 87.19±1.26 
Each value represents the mean±SD (n = 3) 
 
Data analysis and optimization of formula 
Mathematical modeling 
Multiple linear regression analysis (MLRA) and analysis of variance 
(ANOVA) were carried out employing the Design Expert software 8.0.1.0. 
to establish a relationship between the three independent variables (X1, 
X2, and X3) and the three dependent variables (Y1, Y2, and Y3) in the Box 
Behnken design. The results of MLR (the value of the correlation 
coefficient and the values of coefficients) and ANOVA (Fisher’s ratio and 
P values) are summarized in table 3 for the three responses. 
 
Table 3: Analysis of variance (ANOVA) for all responses 
Source Mucoadhesion index (Y1) Gel strength (Y2) Drug release at12hr (Y3) 
Coded 
coefficient 
F Value p value Coded coefficient F value p value Coded coefficient F value p value 
Model 4779.00   146.01   95.30   
X1 1201.87 4.443 0.029 14.36 2.759 0.028 -1.66 1.704 0.028 
X2 2178.75 10.781 0.220 19.53 5.108 0.157 -2.68 4.443 0.068 
X3 1921.88 4.444 0.068 39.20 20.571 0.073 -4.17 10.781 0.011 
X1X2 ---- 0.025 0.011 -25.67 4.411 0.006 -3.78 4.444 0.068 
X1X3 ---- 4.895 0.068 10.90 0.795 0.089 -0.29 0.025 0.877 
X2X3 ---- 1.09 0.877 -6.91 0.319 0.413 -3.97 4.895 0.040 
X12 ----  ---- -19.70 2.396 0.596 ----  ---- 
X22 ----  ---- -38.70 9.252 0.182 ----  ---- 
X32 ----  ---- -46.65 13.445 0.028 ----  ----- 
X12X2 ----  ----   0.014 ----  ---- 
r2 0.973 (Linear)   0.967 (Quadratic)   0.929 (Quadratic)   
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Response Y1-mucoadhesion index 
The high value of the correlation coefficient (0.973) indicates a good 
fit between the independent variables and the first dependent 
variable mucoadhesion index. The linear model was found to be 
significant as the P value is less than 0.05. This result clearly 
demonstrates that at least any one of the selected independent 
variables have a statistically significant influence on the 
mucoadhesion index. Conclusions can be drawn from the numerical 
values of the coefficients of the main effects and interaction effect. 
The most significant retardation effect on the mucoadhesion index 
was shown by the X1 (P = 0.029) and X1X2. This is obvious that gelrite 
which is a polysaccharide increases the crosslinking and due to that 
mucoadhesion also increases. Factor X3should also be considered 
significant at P value is less than 0.1. The reason behind this is the 
polymeric nature of hydroxypropylmethylcellulose (HPMC K4M). 
The contour plot for mucoadhesion index is shown in fig. 3 to 
facilitate understanding by the reader. The contour lines are linear 
in nature in the contour plot since only the main terms (X1 and X2) 
were found significant for mucoadhesion index. The equation in 
terms of un-coded factors is:  
Y1 = 4779.00+1201.87 X1+2178.75 X2+1921.88 X3 
Response Y2–gel strength  
High value of the correlation coefficient (0.967) indicates a good fit 
between the independent variables and gel strength. The quadratic 
model was found to be significant as the P value is less than 0.05. This 
result clearly demonstrates that at least any one of the selected 
independent variables have a statistically significant influence on the 
gel strength. Conclusions can be drawn from the numerical values of 
the coefficients of the main effects, interaction effect, and polynomial 
terms. The most significant effect on gel strength was shown by, X1 
(P = 0.028) and X1X2 as well as some polynomial terms. From the 
polynomial equation, it is clear that as the concentration of gelrite 
increase, the gel strength increases. Factor X3 should also be 
considered significant at P value is less than 0.1. The reason behind 
this is the polymeric nature of hydroxypropylmethylcellulose (HPMC 
K4M). The contour plot for gel strength is shown in fig. 4a, 4b and 4c to 
facilitate understanding by the reader. The contour lines are 
curvilinear in nature. The equation in terms of un-coded factors is:  
Y2 = 146.01+14.36 X1+19.53 X2+39.20 X3-25.67 X1X2+10.90 X1X3-6.91 
X2X3-19.70 X12-38.70 X22-46.65 X32 
Response Y3-drug release at 12h 
High value of the correlation coefficient (0.929) indicates a good fit 
between the independent variables and % cumulative drug released 
at 12 h. The model is significant with a P value of less than 0.05. This 
result clearly demonstrates that at least any one of the selected 
independent variables have a statistically significant influence on 
the % drug released at 12 h. The data are shown in table 3 and fig. 
5a, 5b, and 5c indicate that the concentration of gelrite and 
concentration of hydroxypropylmethylcellulose (HPMC K4M) have 
higher drug retardation effect. The equation in terms of un-coded 
factors is:  
Y3 = 95.30-1.66 X1-2.68 X2-4.17 X3-3.78 X1X2-0.29 X1X3-3.97X2X3 
 
 
Fig. 3: Contour plot (i) and response surface (ii) plot showing the relationship between various levels of polymer (Conc. of gelrite and 
Conc. of tamarind Gum) on MI 
 
  
Fig. 4a: Contour plot (i) and response surface (ii) plot showing the relationship between various levels of polymer (Conc. of gelrite and 
conc. of tamarind gum) on GS 
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Fig. 4b: Contour plot (i) and response surface (ii) plot showing the relationship between various levels of polymer (Conc. of Gelrite and 
Conc. of HPMC K4M) on GS 
 
  
Fig. 4c: Contour plot (i) and response surface (ii) plot showing the relationship between various levels of polymer (Conc. of HPMC K4M and 
Conc. of Tamarind Gum) on GS 
 
 
Fig. 5a: Contour plot (i) and response surface (ii) plot showing the relationship between various levels of polymer (Conc. of gelrite and 
conc. of tamarind gum) on drug release at12h 
 
 
Fig. 5b: Contour plot (i) and response surface (ii) plot showing the relationship between various levels of polymer (Conc. of gelrite and 
conc. of HPMC K4M) on drug release at12h 
Dholakia et al. 




Fig. 5c: Contour plot (i) and response surface (ii) plot showing the relationship between various levels of polymer (Conc. of HPMC K4M and 
conc. of tamarind Gum) on drug release at12h 
 
Design space and validation of response surface methodology 
An ideal product is one which satisfies the requirements of 
mucoadhesion index, gel strength and drug release at 12h to get an 
idea about the acceptable. It is worthwhile to note that FDA requires 
that the design space be clearly defined in ANDA. Optimization was 
achieved by computing overall desirability. The software suggested 
that when the 0.6 % of gelrite, 0.023% of tamarind seed 
polysaccharide and 0.25 % of hydroxypropylmethylcellulose (HPMC 
K4M) (see the square within the overlaid plot), the three requirements. 
To check the reliability of the evolved mathematical models, 
responses were checked through additional random checkpoint 
batches covering the entire range of the experimental domain. By 
the use of grid search analysis, two batches were selected and 
responses were predicted by the mathematical model. These two 
additional batches were prepared, and actual responses were 
recorded. Table 4 shows the composition of check-point 
formulations, predicted and experimental values of responses and 
percentage predicted error. Percentage prediction error is helpful in 
establishing the validity of generated equations and to describe the 
domain of applicability of the RSM model. The prediction error was 
found to vary between 1.08 to 3.65. The low magnitudes of error, as 
well as the significant values of R2 in the present study, prove the 
high predictive ability of RSM. 
  
Table 4: Composition of checkpoint batch formulation predicted the experimental value of the response variable 
Check point batches M* M** M*** 
X1(%) 0.6 0.6 0.6 
X2(%) 0.023 0.035 0.046 
X3(%) 0.25 0.21 0.205 
The predicted value of response Y1(Cps) 5222.38 5441.24 5072.02 
Actual value of response Y1(Cps) 5380 5500 5172 
% Prediction Error 3.01 1.08 1.97 
Predicted value of response Y2(dyne/cm2) 137.06 141.49 136.99 
Actual value of response Y2 (dyne/cm2) 141 145.65 142 
% Prediction Error 2.91 2.94 3.65 
Predicted value of response Y3(%w/w) 98.15 97.37 98.09 
Actual value of response Y3(%w/w) 99.46 99.36 96.02 
% Prediction Error 1.31 2.04 2.11 
#predicted error (%) = (observed value-predicted value)/predicted value×100 %., M* Optimized Batch, M* and M** Check point batches having 
desirability near 0.99 from grid search  
 
Evaluation of in situ gel  
Clarity, pH, viscosity 
Clarity of all formulations was found satisfactory. The formulations were 
light yellow in color. Terminal sterilization with autoclaving had no effect 
on physicochemical properties of the formulation. The pH was within the 
acceptable range (6.8 to 7.4). The successful use of in situ gels for ocular 
delivery is not only dependent on properties after administration but is 
also important that they are easy to administer, by dropping, into the 
eye. It should exhibit low viscosity for reproducible dose administration. 
Gelrite containing formulations were mixed with STF in 1:1 dilution 
showed the drastic difference in viscosity confirming phase transitions 
from sol to gel as gelrite is a cationic sensitive polymer. In this condition, 
formulations possessed Non-Newtonian flow, i.e., by increasing shear 
stress, shear thinning of the formulation was observed. This increasing 
shear rate mimics ocular shear rates associated with normal blinking 
which is extremely wide, ranging from 0.03-28500 S-1. Viscosities of 
prepared formulations were found in a range of 10 to 150 cps and 
exhibited Non-Newtonian flow [20-21].  
Drug content  
Drug content of the prepared in situ gel was in the range of 98-99% 
w/w, excluding any possibility for segregation of drug or additives 
during preparation.  
Mucoadhesive index (MI) 
The mucoadhesive index is an important physicochemical 
parameter for in situ forming ophthalmic gels since it prevents the 
formulation from rapid drainage and hence lengthens its precorneal 
residence time. It shows adhesive forces between polymer molecule 
and mucous membrane. Results of the determination of 
mucoadhesive forces of all the prepared formulations are tabulated 
in table 2 [22].  
Gelation strength (GS)  
Gel strength shows cohesive forces between polymer molecules. All 
formulations exhibited good gel strength. Results of gel strength are 
presented in table 2 [23]. 
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Ocular irritation test 
The optimized batch M* was selected for the ocular irritation test. 
The formulation for instilled daily for 21 d and was found to be non-
irritating with no ocular damage to the cornea, iris or conjunctivae 
and moreover, redness and swelling was also not observed in the 
experimental animals (fig. 6).  
Thus, batch M* was considered as therapeutically safe, efficacious 
and suitable for the ocular delivery of the drug [9]. 
 
 
Fig. 6: Ocular irritation test (A) rabbit eye before ocular irritation test (B) Rabbit eye after ocular irritation test 
 
Stability studies 
Stability study of optimized formulation was performed as per ICH 
guideline. The sample was evaluated for in vivo release study, gel 
strength, mucoadhesive strength, and viscosity. Variation in value 
was found within±3% of initial value. This study shows that no 
change or degradation was found in moxifloxacin hydrochloride in 
situ gel (table 5). 
 
Table 5: Stability study data of optimized formulation 
Parameter 5 d After 15 d After 30 d 
Appearance Acceptable Acceptable Acceptable 
Viscosity 48.01±0.15 48.22±0.14 49.32±0.32 
pH 7.06±0.11 7.10±0.10 7.26±0.11 
Each value represents the mean±SD (n = 3) 
 
CONCLUSION 
In this study, moxifloxacin hydrochloride (MH) in situ gel was 
successfully prepared using gelrite, hydroxypropylmethylcellulose 
(HPMC K4M) and tamarind gum. However, preclinical and clinical studies 
are necessary for commercialization of dosage form. In situ ophthalmic 
gel was optimized using Box Behnken design. The influence of 
quantitative factors was predicted by a polynomial equation. Based on 
optimization, it was concluded that batch containing 0.6 % gelrite, 0.023 
% tamarind gum and 0.25 % hydroxypropylmethylcellulose (HPMC 
K4M) gave maximum residence time and better efficacy. On the basis of 
in vivo ocular irritancy study, it was found that optimized formulation 
was nonirritant. Thus, this dosage form might be a promising delivery 
system of ophthalmic drugs with increased bioavailability. 
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